Targeting integrin pathways: mechanisms and advances in therapy

整合素 医学 纳塔利祖玛 细胞生物学 癌症研究 计算生物学 受体 免疫学 生物 内科学 多发性硬化
作者
Xiaocong Pang,He Xu,Zhiwei Qiu,Hanxu Zhang,Ran Xie,Zhiyan Liu,Yanlun Gu,Nan Zhao,Qian Xiang,Yimin Cui
出处
期刊:Signal Transduction and Targeted Therapy [Springer Nature]
卷期号:8 (1): 1-1 被引量:1069
标识
DOI:10.1038/s41392-022-01259-6
摘要

Abstract Integrins are considered the main cell-adhesion transmembrane receptors that play multifaceted roles as extracellular matrix (ECM)-cytoskeletal linkers and transducers in biochemical and mechanical signals between cells and their environment in a wide range of states in health and diseases. Integrin functions are dependable on a delicate balance between active and inactive status via multiple mechanisms, including protein-protein interactions, conformational changes, and trafficking. Due to their exposure on the cell surface and sensitivity to the molecular blockade, integrins have been investigated as pharmacological targets for nearly 40 years, but given the complexity of integrins and sometimes opposite characteristics, targeting integrin therapeutics has been a challenge. To date, only seven drugs targeting integrins have been successfully marketed, including abciximab, eptifibatide, tirofiban, natalizumab, vedolizumab, lifitegrast, and carotegrast. Currently, there are approximately 90 kinds of integrin-based therapeutic drugs or imaging agents in clinical studies, including small molecules, antibodies, synthetic mimic peptides, antibody–drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapy, imaging agents, etc. A serious lesson from past integrin drug discovery and research efforts is that successes rely on both a deep understanding of integrin-regulatory mechanisms and unmet clinical needs. Herein, we provide a systematic and complete review of all integrin family members and integrin-mediated downstream signal transduction to highlight ongoing efforts to develop new therapies/diagnoses from bench to clinic. In addition, we further discuss the trend of drug development, how to improve the success rate of clinical trials targeting integrin therapies, and the key points for clinical research, basic research, and translational research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
2秒前
2秒前
程xx完成签到,获得积分10
2秒前
3秒前
3秒前
libz发布了新的文献求助10
4秒前
5秒前
losted完成签到,获得积分10
5秒前
6秒前
长尾巴的人类完成签到,获得积分10
6秒前
王诗琪发布了新的文献求助10
7秒前
xiaoxiaoliang发布了新的文献求助10
7秒前
7秒前
7秒前
7秒前
Debbie的应助被开心德地采纳,获得10
7秒前
zxy的应助被开心德地采纳,获得10
8秒前
CarryLJR的应助被cris采纳,获得50
8秒前
04d的应助被开心德地采纳,获得10
8秒前
被风吹过的路的应助被博纳清采纳,获得10
8秒前
赘婿的应助被19950728采纳,获得10
8秒前
上官若男的应助被影墨采纳,获得10
9秒前
Charlie发布了新的文献求助10
9秒前
9秒前
快乐tomato举报求助违规成功
9秒前
sendou举报求助违规成功
9秒前
啥啥啥举报求助违规成功
9秒前
10秒前
10秒前
10秒前
ysy完成签到,获得积分10
11秒前
豆芽菜发布了新的文献求助10
11秒前
sunnymoon给小萌兽的求助进行了留言
12秒前
12秒前
勉乎哉发布了新的文献求助10
12秒前
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178582
求助须知:如何正确求助?哪些是违规求助? 9569391
关于积分的说明 21804062
捐赠科研通 7773535
什么是DOI,文献DOI怎么找? 3432871
关于科研通互助平台的介绍 2556860
邀请新用户注册赠送积分活动 2478451